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ORGAN DONATION, PRESERVATION AND TRANSPLANTATION
Organ transplantation remains the preferred life-saving treatment for most patients with 
end-stage liver and kidney disease, as it can improve patients’ quality of life as well as 
their survival rates1-3. Unfortunately, not every patient on the waiting list can receive an 
organ because of a global shortage of suitable organ grafts. As a result, 12 people die each 
day while waiting for an organ transplant in Europe alone4,5. This problem underlines the 
need for a concerted action within the transplant community to increase the number of 
available organs. This pertains mostly to organs obtained from deceased donors to avoid 
ethical problems related to living organ donation as well as illegal organ trafficking. On an 
international level, this effort has resulted in the establishment of organizations such as the 
Eurotransplant International Foundation, a non-profit organization established to optimize 
the allocation and distribution of organs amongst a number of European countries5. On 
a national level, several countries including The Netherlands have adopted legislation 
that automatically enters their civilians as potential organ donors unless they personally 
object. Another approach to increase the donor pool is to increase the use of organs of 
suboptimal quality. However, this approach mandates an improvement of organ quality 
prior to transplantation in order not to risk poor transplantation outcomes. As the quality 
of the organ graft may be challenged during each step of the transplantation process, this 
approach should encompass strategies and treatments in the donor, but also afterwards 
during organ preservation and in the recipient. To facilitate organ-improving strategies, the 
first step is to understand which injuries the graft endures during the transplantation process. 
ORGAN DONATION 
Both chronic (aging, pre-existing medical conditions) and acute injuries (donor death, 
organ retrieval strategies) in the donor are risk factors for impaired graft survival after 
transplantation6. Of these injuries, donor age is considered a classical risk factor that is 
associated with both short-term and long-term graft survival7,8. However, recent studies 
suggest that biological organ age and not donor age is a better predictor of transplantation 
outcomes9-11. Halloran et al. postulated that the accumulation of aging combined with 
exposure to injury and stressors impairs the ability of an organ to repair and remodel, 
thereby hindering graft survival6. This might explain why we observe a clear difference 
in survival dependent on the type of organ donor used. Of all donor types, organ grafts 
obtained from living donors are superior when compared to those obtained from deceased 
donors. However, the number of living organ grafts is limited, which means that the majority 
of organs used are obtained from decreased donors. Deceased donors can be classified into 
deceased brain-dead (DBD) donors or deceased cardiac death (DCD) donors. Of the two, 




organs continues to increase, particularly since more countries are accepting organs from 
these donors12. In addition, many countries have started using suboptimal organs obtained 
from so-called extended criteria donors (ECD)13. ECD are over 60 years of age, or between 
50-60 years with comorbidities including hypertension, impaired estimated GFR based on 
plasma creatinine (> 1.5 mg/dL), age, and gender, or death by a cerebrovascular incident.
 
When compared to living donation, deceased donation is associated with allograft dysfunction 
or delayed graft function, impaired survival or even higher mortality rates following 
transplantation14-16. This inferiority of deceased donors is caused by pathophysiological 
changes of death. In DBD donors, most commonly cerebrovascular incidents or traumatic 
brain injuries cause increased intracranial pressure. When the body fails to maintain cerebral 
perfusion, this results in ischemia of the brain, and brain stem. As a result, large amounts 
of catecholamines are released and a cascade of derailments commences that includes 
inflammation, hemodynamic instability, and hormonal and metabolic changes17-19. In DCD 
donors, not a cerebral event but cardiopulmonary arrest causes hypoxia, which poses a great 
ischemic insult to the organs. The subsequent prolonged period of warm ischemia adds 
additional ischemic damage to the organs and is considered another risk factor associated 
with impaired graft function and higher mortality rates following transplantation20,21. 
Altogether, this suggests that minimizing and targeting the accumulation of injuries in the 
donor could reduce cellular injury. This strategy could improve graft function and survival 
after transplantation and even allow more organs to be suitable for transplantation. 
Organ preservation
Following this period of donor-related injuries, organ grafts suffer additional injury during the 
preservation period. For decades, organs have been statically preserved on ice. This strategy 
was based on the rate-of-life theory, which states that aging and longevity are regulated 
by the rate of cellular metabolism22. According to this principle, hypothermic preservation 
intends to lower the metabolic rate, thereby reducing hypoxic injury and preserving cellular 
function23. To ensure tolerance of organs to hypothermia, preservation solutions have been 
developed to counter negative side effects of hypothermic preservation including edema, 
accumulation of reactive oxygen species (ROS) production, ATP depletion, mitochondrial 
damage, a switch to anaerobic glycolytic metabolism, and microvascular changes23-25. With 
this in mind, prolonged duration of the cold ischemia is considered an independent risk 
factor for a nonfunctioning or dysfunctioning transplant, particularly in marginal or high-risk 
donors26,27. 
These negative side effects of cold storage have recently led to the first clinical implementation 
of hypothermic machine perfusion (HMP). This technique allows continuous, pulsatile 




and the organ equilibrates with the perfusion solution23. HMP has clear benefits over static 
cold storage in kidney transplantation, evidenced by improved graft function and survival 
rates23,28. Despite these benefits, HMP has only recently begun to be clinically implemented 
in the field of kidney, liver, heart, and lung transplantation. Static cold storage currently 
remains the only clinical preservation method of the pancreas26. Adaptations of HMP that are 
currently being investigated pre-clinically are the addition of oxygen and other additives to 
the perfusion fluid, as well as perfusion at subnormothermic (25°C) or normothermic (37°C) 
temperatures. Especially normothermic temperatures would add the additional benefit of 
allowing viability testing of organs prior to transplantation. The key to all these preservation 
methods is the improvement of graft quality by limiting (the duration of) ischemic injury, 
preventing abrupt reperfusion and preserving or restoring cellular energy supplies. 
Organ transplantation
Optimizing graft quality prior to transplantation is especially important given that the 
reintroduction of warm oxygenated blood in the recipient will only amplify injury to the organ 
graft. After a period of cold ischemia, graft reperfusion causes immediate ROS production 
by the vascular cells of the donor allograft, followed by a subsequent hit of ROS production 
originating from the recipient’s phagocytes29. Interestingly, the initial ROS produced by the 
donor’s vascular cells trigger the subsequent second burst of ROS, together reducing the 
capacity of the anti-oxidant machinery. Hence, this phenomenon has been described as a 
vicious cycle with excess ROS production as its end result29. One of the main contributors 
to this cycle are the mitochondria, which are known to increase their ROS production in 
response to hypoxia30. This ROS production in turn facilitates the initiation of various cellular 
death pathways, including necrosis, apoptosis, and autophagy24,31,32. It is suggested that the 
amount and duration of the oxidative injury related to first ischemia and then reperfusion, 
so-called ischemia-reperfusion injury (IRI), is responsible for the ischemic damage and 
immune activation immediately after transplantation. This makes oxidative stress an 
important factor which can ultimately result in rejection of the organ graft24. Furthermore, 
the level of IRI subsequently determines the extent to which cellular death pathways such 
as autophagy and apoptosis become activated. Their level of activation and interplay seems 





TARGETING BRAIN DEATH-INDUCED INJURY
The potential benefit for patients with organ failure together with the global organ 
shortage is the driving force behind the body of research that has tried to elucidate what 
damages the graft during each step of the transplantation process. Recently, this has led 
to the clinical implementation of ex vivo hypothermic kidney perfusion as the preferred 
preservation method. However, the great potential of targeted treatments during ex vivo 
organ perfusion and the sometimes ethical difficulty of treating deceased donors, should 
not be a reason to refrain from investigating or targeting organ grafts in deceased donors. 
Even though each step of the transplantation process may harm the organ graft, a very 
substantial amount of damage already occurs within the deceased organ donor. Given 
that many intracellular pathways such as oxidative stress and autophagy (introduced 
in more detail later) can be either detrimental or beneficial depending on the level of 
injury or stress, particularly early treatment of donor-related injuries could be of great 
benefit. Besides expanding on the current knowledge on donor pathophysiology, research 
should investigate novel injury mechanisms in the brain-dead donor, such as metabolic 
changes and autophagy dysregulation. Understanding what damages the organ prior to 
transplantation is essential to optimize organ-specific treatments in the donor but also 
during later stages of the transplantation process. Finally, if the outcome of a transplantation 
can already be predicted in the donor or during organ preservation, this would greatly 
benefit the success of transplantations while minimizing the impact on recipients. 
Brain death physiology
Most organs world-wide are obtained from DBD donors12. Brain death is defined as a state 
with irreversible absence of brain and brainstem function, in which mechanical ventilation is 
required to prevent apneas while the systemic circulation remains intact35. Several common 
etiologies of brain death include cerebrovascular accidents, traumatic brain injury, and 
diffuse hypoxia. The common denominator in each of these injuries is a rise in intracranial 
pressure. When the risen cerebral pressure cannot be overcome by a rise in blood pressure, 
this results in hypoperfusion of the brain and subsequent progressive ischemia of the brain, 
brainstem, and ultimately spinal cord. Herniation of the ischemic brain stem results in 
sympathetic hyperactivity that is characterized by an immediate increase in systemic blood 
pressure and peripheral vasoconstriction due to the release of endogenous catecholamines, 
also called the catecholamine storm17,36. This catecholamine storm has been described as 
the body’s final attempt to overcome the rise in intracranial pressure. This vasoconstrictive 
response results in decreased blood flow through peripheral organs such as the liver and 
kidneys37. The systemic hypertension also stimulates (to a lesser extent) parasympathetic 
activity via the baroreceptors, resulting in subsequent bradycardia. These changes, together 




This hypertensive period is followed by a decline in sympathetic tone, which marks the 
beginning of the hemodynamic instability in the DBD donor35. In addition to these changes 
in hemodynamics, ischemia of the brain results in failure of the hypothalamus and pituitary 
axis. As a consequence, a depletion of antidiuretic hormone is evident in the majority of the 
brain-dead donors38. The resulting diabetes insipidus causes increased diuresis and risk of 
hypovolemia and further contributes to the hemodynamically unstable condition. In addition, 
plasma levels of free thyroid hormone, thyroid stimulating hormone, and cortisol generally 
decline39,40. Besides hemodynamic and hormonal changes, BD is characterized as a systemic 
inflammatory state, seen by a rise in circulating cytokines, including interleukin (IL)-6, IL-10, 
MCP-1, and TNF-α41-44. This systemic inflammatory environment triggers a local response in 
the kidneys, liver, and lungs. The inflammatory and apoptotic response in these organs is the 
results of activation of the vascular endothelium, the complement and coagulation system, 
as well as the innate and adaptive immune response45. What triggers this pro-inflammatory 
environment during brain death is not well understood. Nevertheless, cerebral cytokines 
from the dying cerebrum46, complement activation47, translocation of bacteria from the 
intestines48, and organ-specific inflammation49 have all been implicated. Altogether, brain 
death-induced pathophysiology negatively affects organ quality prior to transplantation and 
predisposes the recipients of these grafts to a higher risk of acute rejection, delayed graft 
function and lower survival rates after transplantation16,42,50. Targeting brain death-induced 
injury is, therefore, essential. 
 
AIM OF THIS THESIS
The aim of this thesis is to review and expand on the current knowledge required to target 
brain death-induced injury (see Fig 1). The first part of the thesis (Chapters 1 – 4) focuses on 
interventions in the donor that target brain death-induced pathophysiological changes. The 
second part of this thesis (Chapters 5 – 8) expands on this knowledge by investigating novel injury 
mechanisms pertaining metabolic changes and autophagy (dys)regulation during brain death. 
Interventions in the brain-dead donor
Currently, brain-dead donor management protocols are aimed at targeting brain death-
related pathophysiological changes. Despite considerable differences per individual 
center, protocols have focused mainly on providing hemodynamic support, suppressing 
the immune system, optimizing donor ventilation management, controlling donor body 
temperature, and administrating hormone replacement therapy51. Providing hemodynamic 
support and optimizing organ oxygenation is important, given the hemodynamic instability 
that is evident within the brain-dead donor. Immunosuppressive therapy to counteract 
brain death-induced inflammation is also clinically  relevant, as donor plasma levels of 




free survival54 and an increased risk of recipient death following lung transplantation52-54. 
However, despite promising animal studies56,57, immunosuppressive therapy in brain-dead 
donors has not been able to improve the outcomes of liver and kidney transplantations58-61 
(see Fig 2). Finally, despite mixed reports about the effectiveness of thyroid hormone 
replacement therapies, its use has increased over the years40,62-64. Altogether, this highlights 
that despite the extensive body of preclinical and clinical research on interventions in the 





Figure 1. Targeting brain death-induced injury. Brain death results in hormonal changes, hemodynamic 
instability, inflammation, and oxidative stress. It is unclear how these changes affect organ-specific 
metabolism, perfusion, mitochondrial function, and autophagy. Together these changes negatively 
affect organ quality, which impacts transplantation outcomes and patient and graft survival. Targeting 
brain death-induced injury is essential to optimize organ quality prior to transplantation, particularly 
given the subsequent injuries the graft endures during organ preservation and transplantation, as well 
as the global organ shortage.
 
As a starting point for this thesis in Chapter 2, we provided an update on all systematically 
tested, clinical interventions that have been tested in brain-dead organ donors thus far 
(see Fig 2). Only those studies were included that focused on the effects on organ quality 
and graft and/or patient survival after transplantation. In Chapter 3, we tested whether 
EA230, an oligopeptide of human chorionic gonadotropin with promising anti-inflammatory 
properties in models of septic and haemorrhage shock, would attenuate brain death-induced 
inflammation. Finally, in Chapter 4, we studied whether pre-conditioning of brain-dead 
animals with free thyroid hormone T
3







Figure 2. Overview of all systematically tested, clinical treatments or interventions in the brain-dead donor 
with outcome parameters pertaining the lungs, liver, heart, and kidneys. Treatments or interventions 
denoted in black did not affect graft function or graft and patient survival. Treatments or interventions 
denoted in green were beneficial, those in red were detrimental, and those in orange showed mixed results. 
NOVEL INJURY MECHANISMS
Previous studies have indicated that brain death alters the plasma metabolite profile and 
shifts the balance from aerobic to anaerobic metabolism65. To explain these metabolic 
changes, several theories have been provided. Firstly, these changes have been attributed 
to mitochondrial impairment, as this was previously observed in the muscles of brain-dead 
patients66 and the hearts of brain-dead pigs67. Alternatively, the hemodynamic instability 
and initial organ hypoperfusion immediately following the catecholamine storm have been 




transplantation is of clinical importance, as these changes have been linked to transplantation 
outcomes following both kidney68,69 and liver transplantation70,71. However, effects of donor 
brain death on metabolism in the individual organs has not previously been investigated. 
Therefore, in Chapter 5, we investigated how brain death affects metabolism, both 
systemically as well as in the liver and kidney. Besides studying major metabolic pathways, 
we investigated whether mitochondrial function and organ perfusion were altered during 
brain death. In Chapter 6, we used a non-invasive imaging tool to study in vivo, metabolic 
pathways in the liver and kidney during and following brain death. Using hyperpolarized 
magnetic resonance imaging with MRI-active pyruvate molecules, we were able to visualize 
metabolic pathways in real time during brain death. Afterwards, we visualized glucose 
metabolism during ex vivo organ reperfusion using radioactively labelled glucose. 
Oxidative stress, hemodynamic instability, inflammation, and hormonal perturbances 
induced during brain death are each influencers of autophagy72-74. Autophagy is an intracellular 
degradation pathway that removes, degrades, and recycles cellular constituents75. Autophagy 
normally occurs at a basal level within the cells and serves as a cellular housekeeper that 
removes damaged or unwanted organelles or cellular constituents73,75. Several types 
of autophagy exist, but all types of autophagy involve the transportation of intracellular 
compounds to the lysosomes for degradation. In the presence of cellular stressors such as 
hypoxia, inflammation, or energy depletion, autophagy becomes stimulated and protects 
the cell by removing damaged or toxic cellular products76,77. In this way, autophagy is 
generally considered to be a protective, stress-adaptation pathway that can counter cellular 
death pathways such as apoptosis77,78. Conversely, excessive autophagy stimulation can be 
detrimental and can push the balance away from a protective towards a detrimental role for 
autophagy, as is seen in disease states such as cancer, neurodegeneration, aging, and IRI79,80. 
This is of particular importance, given the current increased use of older and extended 
criteria donors. Even though autophagy has been implicated to play a role during oxidative 
stress and IRI, the exact role that autophagy plays during the transplantation process is only 
beginning to be understood81. In Chapter 7, we reviewed all the available knowledge on 
the role that autophagy and oxidative stress play during each step of the transplantation 
process. Furthermore, we covered the complex interdependency of these two pathways 
and discussed several compounds that target each of these pathways. Finally, in Chapter 
8 we investigated how brain death affects autophagy in the liver and kidney. Furthermore, 
we studied whether stimulation of autophagy with mTOR-inhibitor rapamycin affected 
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